Type　II　pyrethroids　has　been　reported　to　possess　significant　toxicity.　The　analysis　of　type　II　pyrethroid　residues　in　biological　samples　for　clinical　monitoring　and　toxicological　studies　will　be　favorable.　However,　due　to　the　interference　caused　by　complex　matrix　and　the　trace　amount　of　the　pyrethroids,　the　analysis　remains　difficult.　This　study　details　an　efficient　method　employing　magnetic　molecularly　imprinted　polymers　as　a　magnetic　solidphase　extraction　adsorbent　coupled　with　gas　chromatography-mass　spectrometry　for　the　detection　of　type　II　pyrethroids　in　human　plasma.　Molecular　simulations　were　used　to　screen　a　suitable　monomer　and　ratio　of　monomer　to　template　molecule.　A　series　of　functional　nanoparticles　were　synthesized　and　characterized　by　scanning　electron　microscopy,　transmission　electron　microscopy,　X-ray　diffraction　analysis,　Fourier　transform　infrared　spectroscopy　and　vibrating　sample　magnetometer　to　verify　the　coating　of　functional　groups.　Then,　a　binding　experiment　was　employed　to　evaluate　the　adsorption　properties.　According　to　the　results　of　isotherm　study,　the　adsorption　sites　and　capacity　of　MMIPs　are　much　better　than　MNIPs,　while　the　maximum　adsorption　capacity　of　magnetic　molecular　imprinted　polymers　is　27.115　mg　g-1.　The　solid　phase　extraction　conditions　were　investigated,　including　eluent　type,　amount　of　eluent,　extraction　time　and　magnetic　molecular　imprinted　polymers　amount.　The　chromatographic　separation　of　type　II　pyrethroids　in　human　plasma　was　carried　out　by　Gas　Chromatography-Mass　Spectrometry;　Linearity　was　assessed　using　curves　prepared　with　pyrethroids　concentrations　of　0.2,　1,　2,　5,　10,　25,　50　ng　mL-1;　the　coefficients　of　determination　were　more　than　0.990,　and　the　recoveries　are　within　the　range　of　90.0　and　100.1%.　The　limits　of　detection　of　four　pyrethroid　pesticides　were　between　0.005　and　0.032　ng　mL-1;　The　relative　standard　deviation　of　magnetic　molecular　imprinted　polymers　were　2.74-4.07%.　It　was　confirmed　that　the　current　analytical　approach　can　be　applied　for　the　selective　determination　of　type　II　pyrethroids　in　human　plasma　samples　or　other　complex　matrices.